Long‐term response to afatinib in an elderly patient with uncommon epidermal growth factor receptor mutation‐positive lung adenocarcinoma

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors are the standard treatment for patients with non‐small cell lung cancer (NSCLC) harboring EGFR mutations. Uncommon mutations, excluding exon 19 deletions and exon 21 L858R, comprise 7%–23% of EGFR mutation‐positive NSCLC. The treatme...

詳細記述

保存先:
書誌詳細
出版年:Thorac Cancer
主要な著者: Shijubou, Naoki, Sumi, Toshiyuki, Kamada, Koki, Sawai, Takeyuki, Yamada, Yuichi, Nakata, Hisashi, Mori, Yuji, Chiba, Hirofumi
フォーマット: Artigo
言語:Inglês
出版事項: John Wiley & Sons Australia, Ltd 2021
主題:
Case Reports
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7952783/
https://ncbi.nlm.nih.gov/pubmed/33533191
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13869
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料